{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple-negative+Metastatic+Breast+Cancer&page=9",
    "query": {
      "condition": "Triple-negative Metastatic Breast Cancer",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 382,
    "total_pages": 39,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple-negative+Metastatic+Breast+Cancer&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Triple-negative+Metastatic+Breast+Cancer&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T16:20:47.755Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03207867",
      "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NSCLC, Non Small Cell Lung Cancer",
        "RCC, Renal Cell Cancer",
        "Pancreatic Cancer",
        "Urothelial Cancer",
        "Head and Neck Cancer",
        "DLBCL, Diffused Large B Cell Lymphoma",
        "MSS, Microsatellite Stable Colon Cancer",
        "TNBC, Triple Negative Breast Cancer",
        "Melanoma",
        "mCRPC, Metastatic Castration Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "NIR178",
          "type": "DRUG"
        },
        {
          "name": "PDR001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 315,
      "start_date": "2017-08-28",
      "completion_date": "2023-02-14",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-10-14T16:20:47.755Z",
      "location_count": 5,
      "location_summary": "Santa Monica, California • Tampa, Florida • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03207867"
    },
    {
      "nct_id": "NCT05001347",
      "title": "A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Head and Neck Cancer",
        "Non Small Cell Lung Cancer",
        "Gastrointestinal Cancer",
        "Triple Negative Breast Cancer",
        "Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "TJ004309",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "I-Mab Biopharma US Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-11-02",
      "completion_date": "2023-02-08",
      "has_results": true,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-10-14T16:20:47.755Z",
      "location_count": 15,
      "location_summary": "Tucson, Arizona • Whittier, California • Newark, Delaware + 12 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Arlington Heights",
          "state": "Illinois"
        },
        {
          "city": "Covington",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05001347"
    },
    {
      "nct_id": "NCT06264921",
      "title": "A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Solid Tumor, Adult",
        "Advanced Solid Tumor",
        "Metastatic Tumor",
        "Ovarian Cancer",
        "Ovarian Neoplasms",
        "Ovarian Carcinoma",
        "Metastatic Ovarian Carcinoma",
        "Endometrial Cancer",
        "Endometrial Neoplasms",
        "Endometrial Diseases",
        "Metastatic Endometrial Cancer",
        "Metastatic Endometrial Carcinoma",
        "Advanced Endometrial Carcinoma",
        "Advanced Ovarian Carcinoma",
        "Gastric Cancer",
        "Advanced Gastric Carcinoma",
        "Metastatic Gastric Cancer",
        "Metastatic Gastric Carcinoma",
        "Small-cell Lung Cancer",
        "Small Cell Lung Carcinoma",
        "Triple Negative Breast Cancer",
        "Triple Negative Breast Neoplasms",
        "Platinum-resistant Ovarian Cancer",
        "Platinum-refractory Ovarian Carcinoma",
        "CCNE1 Amplification",
        "Hormone Receptor Negative Breast Carcinoma",
        "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
        "Progesterone-receptor-positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "NKT3447",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NiKang Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2024-02-23",
      "completion_date": "2025-04-16",
      "has_results": false,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-10-14T16:20:47.755Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Denver, Colorado • Celebration, Florida + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06264921"
    },
    {
      "nct_id": "NCT04111510",
      "title": "Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Tumor infiltrating lymphocytes (TIL) LN-145",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2019-12-23",
      "completion_date": "2023-05-11",
      "has_results": true,
      "last_update_posted_date": "2024-11-21",
      "last_synced_at": "2026-10-14T16:20:47.755Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04111510"
    },
    {
      "nct_id": "NCT06894771",
      "title": "A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "MK-4700",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2025-04-23",
      "completion_date": "2025-12-08",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-10-14T16:20:47.755Z",
      "location_count": 2,
      "location_summary": "Hackensack, New Jersey • San Antonio, Texas",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06894771"
    },
    {
      "nct_id": "NCT03875313",
      "title": "Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Clear Cell Renal Cell Carcinoma",
        "TNBC - Triple-Negative Breast Cancer",
        "Colorectal Cancer",
        "CRC",
        "RCC",
        "ccRCC"
      ],
      "interventions": [
        {
          "name": "CB-839",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2019-05-20",
      "completion_date": "2020-07-29",
      "has_results": true,
      "last_update_posted_date": "2022-02-17",
      "last_synced_at": "2026-10-14T16:20:47.755Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03875313"
    },
    {
      "nct_id": "NCT03567720",
      "title": "Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "tavokinogene telseplasmid",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Immunopulse",
          "type": "DEVICE"
        },
        {
          "name": "nab paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine plus carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "OncoSec Medical Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2018-10-11",
      "completion_date": "2024-09",
      "has_results": false,
      "last_update_posted_date": "2023-06-01",
      "last_synced_at": "2026-10-14T16:20:47.755Z",
      "location_count": 10,
      "location_summary": "Tucson, Arizona • La Jolla, California • Palo Alto, California + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03567720"
    },
    {
      "nct_id": "NCT04032080",
      "title": "LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Drug 1: LY3023414; Drug 2: Prexasertib",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2019-09-05",
      "completion_date": "2022-11-26",
      "has_results": true,
      "last_update_posted_date": "2023-09-11",
      "last_synced_at": "2026-10-14T16:20:47.755Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04032080"
    },
    {
      "nct_id": "NCT03362060",
      "title": "PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "PVX-410",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2017-12-12",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-10-14T16:20:47.755Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03362060"
    },
    {
      "nct_id": "NCT01186991",
      "title": "Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Onartuzumab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab Placebo",
          "type": "DRUG"
        },
        {
          "name": "Onartuzumab Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 185,
      "start_date": "2011-03",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2017-01-20",
      "last_synced_at": "2026-10-14T16:20:47.755Z",
      "location_count": 23,
      "location_summary": "Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01186991"
    }
  ]
}